医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

EOS imaging Expands Market Presence in South East Asian with First Vietnam Installation

2014年10月07日 AM01:52
このエントリーをはてなブックマークに追加


 

PARIS

EOS imaging (Paris:EOSI) (Euronext, FR0011191766 – EOSI), the pioneer in 2D/3D orthopedic medical imaging, today announces the Company’s continued growth in the South East Asian market with the installation of an EOS® imaging system at the Medic Medical Center (MMC) in Ho Chi Minh City. MMC is the largest radiologic center and medical clinic in Vietnam.

MMC is Vietnam’s most active medical facility in terms of patient volume, providing service to more than 1,000 patients per day, and offers a wide range of specialized services, such as pediatrics, endocrinology, cardiology and neurology. MMC’s network of facilities provides medical services in numerous provinces throughout the country but also in Laos and Cambodia.

Dr. Phan Thanh Hai, Director of the Medic Medical Center at Ho Chi Minh City, said, “As one of the largest medical centers in Vietnam, we must continually seek out proven technologies that will help provide our physicians with the best diagnostic information and our patients with the best treatment outcomes. Our decision to add the EOS system’s low dose 2D/3D imaging satisfies both of those objectives and enables our hospital to continue operating as one of Vietnam’s premier medical facilities.”

The EOS system provides full-body images of patients in a natural functional position in both 2D and 3D with 50% to 85% less dose than digital radiology and 95% less dose than basic CT scans, in accordance with the ALARA (As Low As Reasonably Achievable) principle of radiation reduction.

Marie Meynadier, CEO of EOS imaging, said, “EOS imaging is proud of our continued adoption throughout the South East Asian market with an installation at the Medic Medical Center, which is home to Vietnam’s premier radiologic center. MMC’s decision to become the first in South East Asia to adopt EOS for 2D/3D orthopaedic imaging demonstrates the level of trust and credibility we continue to establish throughout the entire region.”

For further information about the Company or EOS®, the first full body, low dose 2D/3D imaging system, please visit http://www.eos-imaging.com/.

About EOS imaging:

EOS imaging designs, develops, and markets EOS®, a revolutionary and patented medical imaging system, based on technology that enabled George Charpak to win the Nobel Prize for Physics. The Company is authorized to market the system in 33 countries, including the United States (FDA), Japan, Canada, Australia and the European Union (EU). Backed by an installed base of more than 90 sites and by more than 500,000 imaging sessions, EOS® benefits from worldwide recognition within the global medical community. As of December 31, 2013 the Group posted 2013 consolidated revenue of €15.2 million and employed 106 people including an R&D team of 38 engineers. The Group is based in Paris and holds four subsidiaries in Besançon (France), Cambridge (Massachusetts), in Montreal (Canada) and Frankfurt (Germany), and offices in Singapore.

EOS imaging is listed on Compartment C of Euronext Paris

ISIN: FR0011191766 – Ticker: EOSI

Next press release: revenue for the 3rd quarter of 2014, on October 22, 2014 (after market).

CONTACT

EOS imaging
Anne Renevot, +33 (0)1 55 25 61 24
CFO
investors@eos-imaging.com
or
NewCap
Financial
communication and investor relations
Sophie Boulila / Pierre Laurent
+33
(0)1 44 71 94 91
eosimaging@newcap.fr
or
The
Ruth Group (US)

Press relations / Calvin Allen
646-536-7002
callen@theruthgroup.com

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • BioVectra与Keryx Biopharmaceuticals签署枸橼酸铁扩产协议
  • Eternity Healthcare Inc. Enters into Share Exchange Agreement with Guizho Tongren Healthy China Biotechnology Co. Ltd.
  • Takeda and TiGenix announce that Cx601 (darvadstrocel) has received a positive CHMP opinion to treat complex perianal fistulas in Crohn’s disease
  • Chi-Med Initiates Fruquintinib U.S. Clinical Trials
  • Orthocell Granted European Tendon Regeneration Patent